Chenming He

Chenming He

Auto-generated profile, based on publicly available information

Chenming He

Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2024 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
LLLan Liang
Lan Liang
CHChenming He
Chenming He
XHXue Han
Xue Han
JLJia Liu
Jia Liu
LYLiuhong Yang
Liuhong Yang
JLJie Lin
Jie Lin
Background: Precancerous lesions of gastric cancer (PLGC) represent critical stages in gastric cancer progression, with a high risk of malignancy. Current treatments, such as Helicobacter pylori eradication, show limited efficacy in reversing precancerous molecular changes. Zuojin Pill (ZJP), a traditional Chinese medicine, has demonstrated potential for treating digestive disorders and may offer a promising approach for PLGC intervention. Objective: This study aims to investigate the therapeutic effects and mechanisms of ZJP in treating PLGC, focusing on its active components, target pathways, and molecular interactions. By using advanced analytical techniques, we provide a scientific foundation for ZJP’s potential application in early gastric cancer intervention. Methods: Using ultra-high performance liquid chromatography-quadrupole orbitrap high-resolution mass spectrometry (UPLC-Q-Orbitrap HRMS), we identified active components in ZJP. A network pharmacology approach was then applied to construct a “ZJP-compound-target-disease” network. Molecular docking and molecular dynamics simulations were conducted to analyze the stability and interactions of the main active components of ZJP with core protein targets in PLGC. Animal experiments were used to validate significant targets and pathways in vivo. Results: Tangeritin, Isorhamnetin, Caffeic Acid, Azelaic Acid, and Adenosine were identified as the main active components of ZJP in the treatment of PLGC, with key targets including PIK3R1, MAPK3, SRC, JAK2, STAT3, and PIK3CA. Molecular docking and molecular dynamics simulations further confirmed the relationship between compounds and target proteins. The potential molecular mechanism of ZJP predicted by network pharmacology analysis was confirmed in PLGC rats. ZJP downregulated IL-6, TNF-α, c-myc, p-MEK1 and p-ERK1/2, effectively reversing the progression of PLGC. Conclusion: ZJP can reverse MNNG-induced PLGC, potentially through inhibition of the MEK/ERK/c-myc pathway and regulation of cellular proliferation and apoptosis.

1 May 2025 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
CHChenming He
Chenming He
JZJirong Zhang
Jirong Zhang
RZRunze Zhang
Runze Zhang
LLLiang Liu
Liang Liu
JLJielian Luo
Jielian Luo
BFBang-jiang Fang
Bang-jiang Fang
Purpose: This study systematically analyzed available literature related to fragment-based drug design (FBDD) published between 2015 and 2024 using bibliometric methods to identify research trends, hotspots, and emerging frontiers. The findings provide valuable information and a comprehensive reference for future FBDD research and drug development. Methods: The relevant literature was comprehensively searched from the Web of Science Core Collection (WOSCC) database using the keywords “Fragment-based drug design” or “FBDD”, covering articles published between January 1, 2015 and November 1, 2024. A total of 1,301 papers were included. Bibliometric analysis and knowledge mapping were conducted using the RStudio’s bibliometrix-biblioshiny package, CiteSpace, and VOSviewer software, assessing multiple dimensions such as journal co-occurrence, keyword density, institutional collaboration, and citation patterns. Results: The research output in FBDD revealed fluctuating growth, with an average annual growth rate of 1.42%. The United States and China lead global research with 889 and 719 publications, respectively, contributing significantly to international collaboration (34.82%). Prominent research institutions included the Center National de la Recherche Scientifique (CNRS), the University of Cambridge, and the Chinese Academy of Sciences, demonstrating strong academic influence. Key contributors such as Abell, C. Blundell, TL, and Johnson, CN, were among the top ten high-impact authors, significantly shaping the FBDD landscape through highly cited publications. Influential journals included the Journal of Medicinal Chemistry, Journal of Chemical Information and Modeling, and the European Journal of Medicinal Chemistry, each highly recognized within the FBDD research community. Keyword analysis indicated core research directions focused on “fragment-based drug discovery”, “molecular docking”, and “drug discovery”, reflecting key technological advancements and research hotspots. Conclusion: FBDD remains a dynamic field with ongoing global academic attention. Future research directions are likely to emphasize innovations in computational simulation, targeted drug screening, and molecular docking techniques, facilitating the advancement and development of novel therapeutic agents.

31 October 2023 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
CHChenming He
Chenming He
XWXinxin Wu
Xinxin Wu
LLLing Lin
Ling Lin
CLChangya Liu
Changya Liu
MLMin Li
Min Li
BFBang-jiang Fang
Bang-jiang Fang

1 March 2026 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
JZJirong Zhang
Jirong Zhang
NSNing Sun
Ning Sun
CHChenming He
Chenming He
LLLiang Liu
Liang Liu
CWChuanqi Wan
Chuanqi Wan
BFBang-jiang Fang
Bang-jiang Fang
Purpose: To map the research landscape and synthesize randomized evidence on cognitive interventions for adults with chronic lung disease (CLD). Methods: This two-stage study involved: (i) bibliometric mapping of Web of Science Core Collection (WOSCC) (Jan 2005–May 2025) to evaluate output, collaboration, and thematic trends via VOSviewer, CiteSpace, and Bibliometrix; and (ii) narrative synthesis of Randomized Controlled Trials (RCTs) in adults (≥ 18 y) with chronic lung diseases and validated cognitive outcomes, identified from WOSCC, Scopus, and PubMed (to May 1, 2025). Screening, data extraction, and RoB 2 assessment were conducted in duplicate. Results: Bibliometric mapping (2005– 2025) of 3,474 publications showed sustained growth, broad international collaboration, and a shift from epidemiology to mechanisms and patient-centered outcomes. Fifteen RCTs, mostly in stable Chronic Obstructive Pulmonary Disease (COPD), assessed inspiratory-muscle/breathing training, aerobic-resistance or dance exercise, exercise with behavioral/educational components, multimodal cognitive-lifestyle programs, and pharmacological/nutritional or acute physiological therapies Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) were the most common cognitive measures, alongside executive-function tests. Methodological quality was generally moderate. Conclusion: Bibliometrics and randomized-trial synthesis reveal a rapidly growing, globally connected CLD-cognition field moving from epidemiology toward mechanistic and patient-centered research. Multimodal PR, especially exercise and inspiratory-muscle training, shows neurotherapeutic promise, but substantial gaps persist in Low and Middle Income Countries (LMICs) and non-COPD populations.